GSK Shares Fall Despite Strong Q1 as Investors Flag One-Off Boosts
London — Shares of GSK dropped more than 8% on Wednesday, as investors questioned the quality of the company’s first-quarter earnings despite results beating analyst expectations.
The reaction comes early in the tenure of new CEO Luke Miels, who is under pressure to demonstrate sustainable growth and deliver on long-term strategic targets.
Earnings Beat Overshadowed by Concerns
GSK reported core earnings per share of 46.5 pence, exceeding analyst forecasts of 43.3 pence, while quarterly revenue reached £7.6 billion, broadly in line with expectations.
However, investors appeared unconvinced by the strength of the performance, citing concerns that the earnings beat was driven by temporary or one-off factors rather than underlying business momentum.
“Quality concerns around the earnings beat will be in question given that they were driven by one-off factors,” said James Eugene.
Weakness in Core Segments
Analysts also pointed to softer trends in GSK’s general medicines division, including legacy products such as Trelegy, as an additional source of concern.
These dynamics suggest that the headline performance may not fully reflect the company’s underlying growth trajectory.
Leadership Under Pressure to Deliver Growth
Miels, who took over as CEO earlier this year, faces the challenge of convincing investors that GSK can:
- Achieve its £40 billion+ revenue target by 2031
- Strengthen its drug development pipeline
- Navigate the 2028 patent expiry of its key HIV treatment, dolutegravir
Current analyst forecasts fall short of the company’s ambition, projecting approximately £35 billion in revenue by 2031.
Specialty Medicines Remain Stable
GSK’s specialty medicines segment—including HIV and oncology treatments—generated £3.23 billion in sales, in line with expectations.
While this division continues to be a core growth driver, investors are looking for broader diversification beyond HIV-focused revenues.
Pipeline Acceleration a Key Focus
Miels emphasized efforts to accelerate research and development, with plans for 10 late-stage clinical trials across the company’s portfolio this year.
The strategy aims to expand GSK’s presence in high-growth therapeutic areas and reduce reliance on existing blockbuster drugs.
Market Outlook
Despite a roughly 20% rise in GSK’s share price since Miels’ appointment in September, the latest market reaction highlights investor sensitivity to earnings quality and long-term growth visibility.
Going forward, the company’s ability to demonstrate consistent, sustainable performance—supported by pipeline execution and diversification—will be critical in restoring investor confidence.
